Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production

Antibodies used for cancer therapy are monoclonal IgGs, but tumor-targeting IgE antibodies have shown enhanced effector cell potency against cancer in preclinical models. Research-grade recombinant IgE antibodies have been generated and studied for several decades. The recent Phase 1 clinical trial...

詳細記述

書誌詳細

主要な著者:	Heather J Bax, Jitesh Chauhan, Alexandra J McCraw, Melanie Grandits, Chara Stavraka, Heike Lentfer, Tim Hillyer, Simon Carroll, Kim Vigor, Chris Selkirk, Mariangela Figini, Jack Cheeseman, Paulina A Urbanowicz, Richard A Gardner, Daniel I R Spencer, Nigel Westwood, Sarah Mellor, James Spicer, Debra H Josephs, Sophia N Karagiannis
フォーマット:	Artigo
言語:	Inglês
出版事項:	Taylor & Francis Group 2025-12-01
シリーズ:	mAbs
主題:	AllergoOncology antibody immunotherapy basophil activation test cancer good manufacturing practice IgE
オンライン･アクセス:	https://www.tandfonline.com/doi/10.1080/19420862.2025.2451295
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!